PartnershipJul 6, 2026, 04:17 PM
RxSight and Alcon Partner for PCIOLs; RxSight Gets $60M Upfront
AI Summary
RxSight, Inc. and Alcon have announced a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting intraocular lenses (PCIOLs). Under the agreement, RxSight will receive a $60 million upfront payment and could earn up to an additional $140 million in milestone payments. The partnership aims to combine RxSight's post-operative light-adjustable technology with Alcon's PCIOL optical designs to enable fine-tuning of visual outcomes after cataract surgery. Alcon will handle global commercialization, while RxSight will manage development and manufacturing and receive royalties on net sales.
Key Highlights
- RxSight and Alcon announced a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting intraocular lenses (PCIOLs).
- RxSight will receive a $60 million upfront payment for development.
- RxSight could receive up to an additional $140 million in payments for development and regulatory milestones.
- Alcon will lead global commercialization of the co-developed technology.
- RxSight will be responsible for development and manufacturing and will receive royalties on net sales.
- The collaboration combines RxSight's light-adjustable technology with Alcon's PCIOL optical designs.
Price Impact
More from RXST